1. A 28-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) — a clonal hematopoietic disorder in which erythrocytes lack GPI-anchored complement regulatory proteins — is started on eculizumab. Her hematologist explains that the drug works by binding to a specific complement protein, preventing its cleavage and thereby halting the downstream inflammatory cascade and lytic pathway. Which of the following best describes the mechanism of action of eculizumab?
A) It binds C3b and blocks the formation of both the classical and alternative pathway C3 convertases, preventing all downstream complement amplification.
B) It binds the C5a receptor 1 (C5aR1) on neutrophils and macrophages, blocking C5a-mediated inflammatory signaling without affecting the membrane attack complex.
C) It binds C5 with high affinity, preventing its cleavage into C5a and C5b, thereby blocking both C5a-mediated inflammation and membrane attack complex (MAC) formation.
D) It binds C1q and prevents activation of the classical pathway C3 convertase, selectively blocking immune complex-triggered complement activation.
E) It degrades C3b on erythrocyte surfaces by acting as a cofactor for Factor I-mediated proteolysis, restoring complement regulation in PNH cells.
ANSWER: C
Rationale:
Eculizumab is a humanized IgG2/IgG4 hybrid monoclonal antibody that binds C5 (complement component 5) with high affinity, preventing its cleavage by the C5 convertase into C5a and C5b. Blocking this single step simultaneously prevents C5a-mediated inflammation (neutrophil priming, degranulation, chemotaxis) and MAC (membrane attack complex) formation (which causes intravascular lysis of complement-susceptible erythrocytes in PNH). Critically, upstream C3b opsonization remains intact because C3 cleavage is unaffected.
Option A: Option A is incorrect because the agent described — a C3/C3b inhibitor — corresponds to pegcetacoplan, not eculizumab; eculizumab acts downstream of C3.
Option B: Option B is incorrect because blocking C5aR1 is the mechanism of avacopan, an oral small-molecule antagonist approved for ANCA-associated vasculitis; avacopan does not prevent C5 cleavage itself.
Option D: Option D is incorrect because eculizumab has no effect on C1q or the classical pathway C3 convertase; it acts specifically at C5, a downstream terminal complement protein.
Option E: Option E is incorrect because Factor I-mediated C3b degradation describes the physiological function of host complement regulatory proteins such as Factor H and CD46 (MCP, membrane cofactor protein), not the mechanism of eculizumab.
2. A 34-year-old man with atypical hemolytic uremic syndrome (aHUS) — a thrombotic microangiopathy caused by uncontrolled alternative pathway complement activation — is being evaluated for eculizumab therapy. His physician explains that before starting the drug, a specific infection risk must be addressed with vaccination. Which of the following best explains why complement inhibitors create a mandatory vaccination requirement, and which organism is the primary concern?
A) Complement inhibitors suppress all T-cell-mediated immunity, requiring vaccination against Streptococcus pneumoniae to prevent invasive pneumococcal disease before therapy begins.
B) The terminal complement complex (MAC) is the primary defense against Neisseria meningitidis; blocking terminal complement with eculizumab or any complement inhibitor creates a profound susceptibility to meningococcal disease, requiring vaccination with both ACWY conjugate and MenB vaccines before the first dose.
C) Complement inhibitors impair opsonization by blocking C3b deposition on bacterial surfaces, creating specific vulnerability to encapsulated organisms including Haemophilus influenzae type b, for which vaccination is required.
D) Anti-C5 therapy eliminates C5a-mediated neutrophil chemotaxis, abolishing phagocytic recruitment to sites of infection and requiring pneumococcal and meningococcal vaccination before initiation.
E) Eculizumab depletes circulating natural killer cells through ADCC (antibody-dependent cellular cytotoxicity), requiring live-attenuated vaccination against herpesvirus infections before starting therapy.
ANSWER: B
Rationale:
The terminal complement complex — the MAC (membrane attack complex) assembled from C5b plus C6, C7, C8, and polymerized C9 — is the primary bactericidal defense against encapsulated Gram-negative bacteria, particularly Neisseria meningitidis (meningococcus). Eculizumab and all other complement inhibitors (ravulizumab, pegcetacoplan, iptacopan, danicopan) prevent MAC formation either directly (anti-C5 agents) or indirectly (upstream inhibitors), creating a profound and persisting susceptibility to meningococcal disease, which can be fulminant and fatal within hours. Mandatory requirements before any complement inhibitor include the meningococcal ACWY polysaccharide conjugate vaccine AND the MenB vaccine (meningococcal serogroup B) at least two weeks before the first dose, with prophylactic antibiotics (penicillin V or amoxicillin) started if treatment cannot be delayed.
Option A: Option A is incorrect because complement inhibitors do not suppress T-cell immunity; pneumococcal vulnerability is driven by impaired C3b opsonization, and while pneumococcal vaccination is recommended in immunosuppressed patients generally, it is not the primary mandatory requirement specific to complement inhibitors.
Option C: Option C is incorrect because the opsonization function of C3b is largely preserved with anti-C5 therapy (eculizumab blocks downstream of C3); the specific concern is MAC-mediated lysis of Neisseria, not opsonization of H. influenzae.
Option D: Option D is incorrect because C5a inhibition by eculizumab does reduce C5a-mediated neutrophil chemotaxis, but this is not the mechanism driving the mandatory meningococcal vaccination requirement; the primary mechanism is loss of MAC bactericidal activity against Neisseria.
Option E: Option E is incorrect because NK cell depletion is a mechanism associated with daratumumab (anti-CD38), not with eculizumab or other complement inhibitors; herpesvirus prophylaxis is not the mandatory pre-treatment requirement for complement inhibitor initiation.
3. A 45-year-old woman with refractory dermatomyositis is treated with high-dose intravenous immunoglobulin (IVIG) at 2 g/kg over five days. Her rheumatologist explains that one mechanism by which IVIG reduces pathogenic autoantibody levels is through receptor saturation at high doses. Which of the following best describes this mechanism?
A) High-dose IVIG activates regulatory T cells (Tregs) through Fc-gamma receptor signaling on dendritic cells, suppressing autoreactive T-cell proliferation and reducing autoantibody-producing B-cell activation.
B) IVIG provides anti-idiotypic antibodies that directly bind and neutralize the antigen-binding regions of pathogenic autoantibodies, lowering their functional titer without affecting total IgG levels.
C) High-dose IVIG activates the classical complement pathway through Fc-mediated C1q binding, consuming complement components and reducing complement-mediated tissue injury in dermatomyositis.
D) At high doses, IVIG saturates the neonatal Fc receptor (FcRn) — the receptor responsible for IgG recycling and extended half-life — causing accelerated catabolism of all circulating IgG including pathogenic autoantibodies, reducing their plasma half-life by 10 to 14 days.
E) IVIG blocks Fc-gamma receptors (FcgammaRII and FcgammaRIII) on splenic macrophages, preventing phagocytosis of autoantibody-opsonized cells and reducing autoantibody consumption without lowering autoantibody production.
ANSWER: D
Rationale:
The neonatal Fc receptor (FcRn) is responsible for the extended half-life of IgG (~21 days) by binding IgG in acidic endosomes and recycling it back to the circulation, preventing lysosomal degradation. At high IVIG doses (typically 1 to 2 g/kg), the massive IgG load saturates FcRn binding capacity; endogenous IgG — including pathogenic autoantibodies — can no longer be rescued from lysosomal degradation at the same rate, resulting in accelerated catabolism that shortens the effective circulating half-life of pathogenic IgG and produces a measurable net reduction in autoantibody levels over approximately 10 to 14 days. This is the dominant mechanism in antibody-mediated autoimmune diseases such as myasthenia gravis, pemphigus vulgaris, and dermatomyositis.
Option A: Option A is incorrect because while IVIG does have some Treg-activating effects, this is not the FcRn-mediated catabolism mechanism described in the question; Treg activation is a secondary immunomodulatory effect of lower clinical significance.
Option B: Option B is incorrect because anti-idiotypic antibody neutralization is a real IVIG mechanism but is dose-independent; it does not account for the FcRn saturation-driven reduction in total autoantibody half-life specifically associated with high-dose IVIG.
Option C: Option C is incorrect because IVIG does not activate the classical complement pathway through C1q binding in a therapeutically relevant manner; IVIG actually modulates complement by providing anti-idiotypic antibodies and through other mechanisms, but complement consumption is not the mechanism being described here.
Option E: Option E is incorrect because Fc-gamma receptor blockade on macrophages is the mechanism most relevant in ITP (immune thrombocytopenic purpura), where it prevents platelet phagocytosis; it is a distinct mechanism from FcRn saturation and does not reduce autoantibody production or circulating levels.
4. A 52-year-old woman with moderate-to-severe seropositive rheumatoid arthritis (RA) — with positive anti-CCP (anti-cyclic citrullinated peptide) antibodies and rheumatoid factor — fails to respond adequately to methotrexate and is started on abatacept. Her rheumatologist explains that the drug works by interfering with the co-stimulatory signal required for full T-cell activation. Which of the following best describes the mechanism of abatacept?
A) Abatacept is a recombinant fusion protein of the extracellular domain of CTLA-4 (cytotoxic T-lymphocyte antigen 4) fused to IgG1 Fc; because CTLA-4 binds CD80 and CD86 on antigen-presenting cells with far higher affinity than CD28, abatacept competitively blocks CD28 co-stimulation, rendering antigen-specific T cells anergic.
B) Abatacept is a monoclonal antibody that binds CD28 on T cells directly, preventing its engagement by CD80 or CD86 and blocking the co-stimulatory signal required for T-cell proliferation and differentiation.
C) Abatacept blocks PD-1 (programmed cell death protein 1) signaling on T cells, activating inhibitory checkpoints that reduce autoreactive T-cell responses in the inflamed synovium of rheumatoid arthritis.
D) Abatacept binds the TCR (T-cell receptor)-CD3 complex on T cells, preventing antigen-specific activation at the primary signal rather than the co-stimulatory checkpoint, producing broad T-cell suppression.
E) Abatacept is a fusion protein of IL-2 (interleukin-2) receptor alpha (CD25) and IgG Fc that captures circulating IL-2, depriving autoreactive T cells of the proliferation signal required after antigen engagement and co-stimulation.
ANSWER: A
Rationale:
Full T-cell activation requires two signals: the primary TCR-mediated antigen recognition signal, and a co-stimulatory signal delivered by engagement of CD28 on T cells by its ligands CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs). Abatacept is a CTLA-4-Ig fusion protein — the extracellular domain of CTLA-4 fused to IgG1 Fc. CTLA-4 naturally competes with CD28 for binding to CD80/CD86 but with approximately 500 to 2500-fold higher affinity; by presenting CTLA-4 as a circulating fusion protein, abatacept occupies CD80 and CD86 on APCs, preventing CD28 engagement, delivering an incomplete first signal without co-stimulation, and driving antigen-specific T cells into anergy or apoptosis.
Option B: Option B is incorrect because abatacept does not bind CD28 on T cells directly; it binds CD80 and CD86 on APCs, blocking those ligands from engaging CD28.
Option C: Option C is incorrect because blocking PD-1 is the mechanism of checkpoint inhibitor cancer immunotherapy (nivolumab, pembrolizumab); abatacept activates the CTLA-4 inhibitory checkpoint rather than blocking PD-1, and these are opposite therapeutic directions.
Option D: Option D is incorrect because abatacept has no effect on the TCR-CD3 complex or primary antigen recognition; it specifically targets the co-stimulatory checkpoint.
Option E: Option E is incorrect because the mechanism described (IL-2 capture via soluble CD25-Fc fusion) is not the mechanism of abatacept; it describes a hypothetical IL-2 trap distinct from the co-stimulation blockade mechanism.
5. A 31-year-old man with PNH (paroxysmal nocturnal hemoglobinuria) is well-controlled on eculizumab but finds the every-two-week intravenous infusion schedule burdensome given his work travel demands. His hematologist discusses switching to ravulizumab, which has the same mechanism but a significantly extended dosing interval. Which of the following best explains the pharmacokinetic basis for ravulizumab's less frequent dosing compared to eculizumab?
A) Ravulizumab binds C5 at a different epitope than eculizumab, resulting in slower dissociation from C5 and a longer duration of complement inhibition despite a similar plasma half-life.
B) Ravulizumab is subcutaneously administered, resulting in slower absorption and a more sustained drug concentration profile than intravenous eculizumab.
C) Ravulizumab is a fully human antibody rather than a humanized antibody, substantially reducing immunogenicity and anti-drug antibody formation, which prolongs its effective half-life in vivo.
D) Ravulizumab carries a polyethylene glycol (PEG) modification that reduces renal filtration and slows antibody catabolism, extending its plasma half-life to approximately 49 to 52 days compared to 11 days for eculizumab.
E) Ravulizumab was engineered from eculizumab through four amino acid substitutions that increase its affinity for the neonatal Fc receptor (FcRn), enhancing IgG recycling and extending plasma half-life from approximately 11 days to approximately 49 to 52 days, enabling every-8-week maintenance dosing in adults.
ANSWER: E
Rationale:
Ravulizumab is derived from eculizumab through four strategic amino acid substitutions in the IgG4 Fc region that alter its pH-dependent binding to C5 and substantially increase its affinity for the neonatal Fc receptor (FcRn). The FcRn recycles IgG from endosomes back into circulation, and higher FcRn affinity means more efficient recycling and a dramatically extended plasma half-life — from approximately 11 days for eculizumab to approximately 49 to 52 days for ravulizumab. This pharmacokinetic difference translates directly into clinical dosing: eculizumab requires intravenous infusions every two weeks during maintenance, while ravulizumab requires infusions every eight weeks in adults after an initial loading dose. The mechanism of action (C5 blockade), indications (PNH, aHUS, gMG, NMOSD), and safety requirements (meningococcal vaccination) are identical for both agents.
Option A: Option A is incorrect because while ravulizumab does have engineered altered C5 binding kinetics (pH-dependent C5 release), the primary pharmacokinetic advantage is FcRn-mediated extended half-life, not simply slower C5 dissociation.
Option B: Option B is incorrect because ravulizumab, like eculizumab, is administered intravenously; it is not a subcutaneous formulation.
Option C: Option C is incorrect because the extended half-life of ravulizumab is due to FcRn engineering, not to its human vs. humanized status; both eculizumab and ravulizumab are humanized antibodies with low immunogenicity.
Option D: Option D is incorrect because PEG modification describes the mechanism of pegcetacoplan (a pegylated cyclic peptide C3 inhibitor), not ravulizumab; ravulizumab is an unmodified monoclonal antibody whose extended half-life is conferred by Fc engineering.
6. A 58-year-old man is diagnosed with granulomatosis with polyangiitis (GPA) — a form of ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis — and started on rituximab plus avacopan as part of an induction regimen designed to minimize corticosteroid use. His physician explains that avacopan targets a specific complement receptor to interrupt the neutrophil-driven destructive cycle in the renal glomerulus. Which of the following best describes avacopan's mechanism and approved indication?
A) Avacopan is an intravenous anti-C5 monoclonal antibody that prevents MAC formation in the renal microvasculature, reducing endothelial damage in ANCA vasculitis by blocking terminal complement lysis.
B) Avacopan is a subcutaneous anti-C3 fusion protein that inhibits C3 cleavage by all three complement activation pathways, providing upstream blockade of both C5a generation and C3b-mediated neutrophil opsonization in vasculitis.
C) Avacopan is an oral small-molecule antagonist of C5aR1 (C5a receptor 1, CD88) that blocks C5a binding on neutrophils and macrophages, preventing C5a-mediated neutrophil priming and tissue infiltration; it is approved for ANCA-associated vasculitis (GPA and MPA) as a steroid-sparing agent.
D) Avacopan is an oral factor D inhibitor that selectively blocks alternative pathway amplification, preventing ANCA-activated neutrophil complement priming in the renal glomerulus without affecting the classical or lectin pathways.
E) Avacopan is an intravenous monoclonal antibody targeting ANCA (anti-PR3 and anti-MPO antibodies) directly, neutralizing them before they can prime neutrophils and preventing glomerular injury in GPA and MPA.
ANSWER: C
Rationale:
Avacopan is an oral small-molecule antagonist of C5aR1 (C5a receptor 1, also called CD88), the receptor through which C5a exerts its pro-inflammatory effects on neutrophils, monocytes, macrophages, and endothelial cells. In ANCA-associated vasculitis (AAV), ANCA-primed neutrophils release granule contents and generate additional C5a, creating a destructive positive-feedback loop; blocking C5aR1 interrupts this cycle, reducing neutrophil degranulation, reactive oxygen species production, and tissue infiltration at the glomerulus and lung. Avacopan is approved for GPA (granulomatosis with polyangiitis) and MPA (microscopic polyangiitis) in combination with rituximab or cyclophosphamide; the ADVOCATE trial demonstrated non-inferiority to high-dose corticosteroid taper for remission induction and superiority for sustained remission at 52 weeks. Crucially, avacopan preserves MAC formation (since it acts downstream of C5 cleavage at the receptor level), which may reduce the catastrophic meningococcal risk inherent to anti-C5 agents.
Option A: Option A is incorrect because avacopan is not an anti-C5 monoclonal antibody; it is an oral C5aR1 antagonist that does not prevent C5 cleavage or MAC formation.
Option B: Option B is incorrect because avacopan has no effect on C3; it acts downstream at the C5a receptor level, and C3 inhibition is the mechanism of pegcetacoplan.
Option D: Option D is incorrect because Factor D inhibition describes the mechanism of danicopan, not avacopan; danicopan is an alternative pathway inhibitor used as add-on therapy for PNH, not for ANCA vasculitis.
Option E: Option E is incorrect because avacopan does not target ANCA antibodies directly; it targets the C5a receptor to interrupt the complement-neutrophil amplification loop driven by ANCA activation.
7. A 24-year-old woman presents with severe immune thrombocytopenic purpura (ITP) — a condition in which anti-platelet antibodies lead to platelet destruction — and a platelet count of 8,000/mcL with mucosal bleeding. She is treated with high-dose IVIG. Which of the following best describes the mechanism by which IVIG raises the platelet count in ITP?
A) IVIG saturates the neonatal Fc receptor (FcRn), accelerating catabolism of the anti-platelet IgG autoantibodies and rapidly reducing the titer of antibodies opsonizing platelet surfaces.
B) IVIG provides exogenous IgG Fc regions that competitively block Fc-gamma receptors (FcgammaRII and FcgammaRIII) on splenic macrophages, preventing macrophage recognition and phagocytosis of anti-platelet antibody-opsonized platelets.
C) IVIG contains anti-idiotypic antibodies that directly neutralize the antigen-binding sites of anti-platelet autoantibodies, preventing their binding to platelet surface glycoproteins and reducing opsonization.
D) IVIG activates regulatory T cells through dendritic cell Fc-gamma receptor signaling, suppressing autoreactive B-cell activation and reducing new anti-platelet antibody production within days of infusion.
E) IVIG modulates complement activation by providing exogenous IgG that competitively inhibits C1q binding to anti-platelet antibody-opsonized platelets, preventing complement-mediated platelet lysis in the spleen.
ANSWER: B
Rationale:
In ITP, anti-platelet IgG antibodies (typically directed against platelet glycoprotein IIb/IIIa or Ib/IX) opsonize platelets; splenic macrophages recognize these opsonized platelets via Fc-gamma receptors (FcgammaRII, CD32, and FcgammaRIII, CD16) and phagocytose them, driving thrombocytopenia. At high doses, IVIG provides a massive bolus of IgG Fc regions that saturate and block these macrophage Fc-gamma receptors, preventing phagocytic recognition of opsonized platelets and allowing platelet counts to recover. This mechanism explains the rapid platelet response typically seen within 24 to 72 hours of IVIG infusion in ITP.
Option A: Option A is incorrect because while FcRn saturation and accelerated autoantibody catabolism is a real IVIG mechanism, it operates over 10 to 14 days and does not account for the rapid platelet response in acute ITP; Fc-gamma receptor blockade is the more immediate and dominant mechanism in ITP.
Option C: Option C is incorrect because anti-idiotypic neutralization is a dose-independent mechanism that contributes to long-term autoimmune modulation; it is not the primary mechanism of rapid platelet recovery in acute ITP.
Option D: Option D is incorrect because Treg activation by IVIG is a secondary immunomodulatory effect that operates over days to weeks; it does not explain the rapid platelet response in acute ITP and is not considered the primary mechanism of action in this context.
Option E: Option E is incorrect because complement-mediated platelet lysis plays a minor role in typical ITP compared to Fc-mediated phagocytosis; blocking C1q is not a recognized mechanism of IVIG in ITP.
8. A 19-year-old man undergoes deceased-donor kidney transplantation. His transplant team is considering belatacept as an alternative to calcineurin inhibitor-based immunosuppression to preserve long-term renal allograft function. Pre-transplant serologic testing reveals he is EBV (Epstein-Barr virus)-seronegative. Which of the following best explains why his serostatus is a contraindication to belatacept?
A) EBV-seronegative recipients have impaired T-cell memory against common pathogens, and belatacept's calcineurin-independent mechanism of action fails to provide adequate immunosuppression in the absence of prior viral antigen exposure.
B) EBV-seronegative patients have higher levels of circulating CD28-expressing naive T cells, making them more resistant to co-stimulation blockade by belatacept and significantly increasing the risk of acute allograft rejection.
C) Belatacept depletes B cells by Fc-mediated mechanisms, and EBV-seronegative recipients who acquire primary EBV infection after B-cell depletion have an elevated risk of overwhelming EBV septicemia.
D) EBV-seronegative recipients who acquire primary EBV infection after transplantation are at substantially increased risk of post-transplant lymphoproliferative disorder (PTLD) — a potentially fatal B-cell lymphoproliferative condition — because belatacept's T-cell co-stimulation blockade impairs EBV-specific cytotoxic T-cell immune surveillance of EBV-infected B cells.
E) EBV-seronegative status indicates an immature immune system with reduced Fc-gamma receptor expression, and belatacept's CTLA-4-Ig Fc domain triggers paradoxical immune activation through these receptors, increasing rejection risk.
ANSWER: D
Rationale:
Belatacept is a second-generation CTLA-4-Ig fusion protein (with L104E and A29Y substitutions conferring ~10-fold higher CD80/86 affinity than abatacept) approved for kidney transplant rejection prophylaxis. EBV-seronegative recipients who undergo transplantation and subsequently acquire primary EBV infection face dramatically elevated risk of post-transplant lymphoproliferative disorder (PTLD) — a spectrum of B-cell lymphoproliferative conditions ranging from polyclonal B-cell proliferation to aggressive monoclonal lymphoma. The reason this risk is amplified specifically with belatacept is that the drug's T-cell co-stimulation blockade impairs EBV-specific cytotoxic T-lymphocyte (CTL) surveillance: CD8+ CTLs normally eliminate EBV-infected B cells, but the CD28 co-stimulation required for CTL priming and effector differentiation is blocked by belatacept, allowing unchecked EBV-infected B-cell proliferation. EBV-seronegative status is therefore a contraindication to belatacept per the FDA label.
Option A: Option A is incorrect because impaired T-cell memory in EBV-seronegative recipients has no direct relationship to the adequacy of belatacept immunosuppression; the concern is specifically EBV-related PTLD risk, not insufficient immunosuppression.
Option B: Option B is incorrect because the level of naive CD28+ T cells does not account for the belatacept contraindication in EBV-seronegative recipients; belatacept does carry a higher rate of acute rejection than calcineurin inhibitors, but the seronegative contraindication is specifically about PTLD risk.
Option C: Option C is incorrect because belatacept does not deplete B cells; it is a T-cell co-stimulation blocker; B-cell depletion is the mechanism of rituximab and other anti-CD20 agents.
Option E: Option E is incorrect because this describes a pharmacologically implausible mechanism; belatacept's Fc region does not cause paradoxical immune activation related to EBV serostatus or Fc-gamma receptor expression.
9. A 44-year-old woman with refractory lupus nephritis has persistent high anti-dsDNA titers and active nephritis despite rituximab therapy. Her nephrologist explains that rituximab failed because it cannot eliminate the cells responsible for ongoing antibody production in this setting, and proposes adding bortezomib to specifically target those cells. Which of the following best explains why plasma cells are selectively vulnerable to bortezomib and why rituximab alone is insufficient?
A) Plasma cells are selectively vulnerable to bortezomib because their exceptionally high rate of immunoglobulin synthesis generates a massive load of misfolded proteins that must be cleared by the 26S proteasome; bortezomib inhibits this proteasome, causing unfolded protein response (UPR) overload and apoptosis. Rituximab is insufficient because long-lived plasma cells lack CD20 expression and are not targeted by anti-CD20 therapy.
B) Plasma cells are selectively vulnerable to bortezomib because they express high levels of CD20, making them responsive to the antibody-dependent cellular cytotoxicity triggered by bortezomib; rituximab fails because its Fc region is inefficiently recognized by plasma cell NK-cell effectors.
C) Bortezomib inhibits BTK (Bruton tyrosine kinase) in plasma cells, blocking the BCR (B-cell receptor) signaling required for continued antibody secretion; rituximab fails because anti-CD20 therapy cannot penetrate the bone marrow plasma cell niche.
D) Plasma cell vulnerability to bortezomib arises from their high expression of CD38, which is the target of bortezomib; rituximab fails because it targets CD19 rather than the CD38 expressed at high levels on long-lived plasma cells.
E) Bortezomib depletes long-lived plasma cells by blocking APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor) signaling in the bone marrow niche, depriving plasma cells of survival signals; rituximab fails because it only depletes circulating B cells, not bone marrow-resident plasma cells.
ANSWER: A
Rationale:
Long-lived plasma cells are terminally differentiated antibody-secreting cells that have exited the cell cycle and lost expression of CD20 and other B-cell surface markers, rendering them invisible to rituximab (anti-CD20). They continue to secrete pathogenic autoantibodies for years from survival niches in the bone marrow. Plasma cells are uniquely vulnerable to proteasome inhibition because they sustain an extremely high rate of immunoglobulin synthesis, generating a large burden of misfolded or unassembled protein chains that must be processed through the unfolded protein response (UPR) and degraded by the 26S proteasome. Bortezomib inhibits the beta5 subunit (chymotrypsin-like catalytic subunit) of the 20S proteasome core, blocking this degradation, causing misfolded immunoglobulin accumulation, activating the terminal UPR pathway (through IRE1, PERK, and ATF6), and driving plasma cell apoptosis.
Option B: Option B is incorrect because plasma cells do not express CD20; they are not targets for antibody-dependent cellular cytotoxicity via CD20, and bortezomib does not work through an ADCC mechanism.
Option C: Option C is incorrect because bortezomib is a proteasome inhibitor, not a BTK inhibitor; BTK inhibition by ibrutinib or acalabrutinib affects B-cell and precursor signaling but is a distinct mechanism.
Option D: Option D is incorrect because while CD38 is indeed highly expressed on plasma cells, the mechanism of bortezomib is proteasome inhibition — not CD38 targeting; anti-CD38 therapy is the mechanism of daratumumab.
Option E: Option E is incorrect because APRIL and BAFF signaling blockade is the mechanism of belimumab (anti-BAFF) and telitacicept (anti-APRIL/BAFF dual); bortezomib's mechanism is proteasome inhibition and UPR-driven apoptosis, not survival niche disruption.
10. A 37-year-old man with PNH (paroxysmal nocturnal hemoglobinuria) has been on eculizumab for two years with excellent control of intravascular hemolysis and no breakthrough thrombotic events. However, he remains persistently anemic with a hemoglobin of 9.2 g/dL, and his hematologist identifies ongoing extravascular hemolysis as the cause. The physician explains that a specific limitation of anti-C5 therapy explains this residual anemia. Which of the following best explains the mechanism and names the agent approved to address this problem?
A) Ongoing extravascular hemolysis on eculizumab is caused by persistent MAC formation on a subpopulation of PNH erythrocytes with partial CD59 expression; adding ravulizumab, which blocks C5 with higher affinity, eliminates this residual MAC-mediated lysis.
B) Eculizumab's every-two-week dosing creates trough periods of incomplete C5 blockade, allowing brief bursts of intravascular hemolysis that are classified as extravascular by laboratory testing; switching to ravulizumab with its extended half-life resolves this problem.
C) Extravascular hemolysis on eculizumab is caused by danicopan-sensitive alternative pathway amplification that generates C5a-driven macrophage activation in the spleen; adding danicopan to eculizumab eliminates this pathway.
D) Anti-C5 therapy causes paradoxical upregulation of the alternative pathway C3 convertase, generating excess C3b deposition on PNH erythrocytes and driving extravascular hemolysis; iptacopan as monotherapy corrects this by blocking Factor B-mediated C3 convertase assembly.
E) Anti-C5 therapy blocks MAC formation but does not prevent C3 cleavage; C3b continues to deposit on PNH erythrocytes, opsonizing them for reticuloendothelial phagocytosis in the liver and spleen (extravascular hemolysis). Pegcetacoplan, a C3 inhibitor, blocks both intravascular and extravascular hemolysis and is approved for PNH including patients with residual extravascular hemolysis on anti-C5 therapy.
ANSWER: E
Rationale:
The key pharmacological insight in PNH management is that eculizumab (and ravulizumab) block C5 cleavage, preventing MAC-mediated intravascular lysis, but leave the upstream C3 step fully intact. In PNH erythrocytes lacking CD55 and CD59, uncontrolled complement continues to deposit C3b on red cell surfaces; C3b-opsonized erythrocytes are recognized by complement receptors on macrophages in the liver (Kupffer cells) and spleen and removed by phagocytosis — a process called extravascular hemolysis. This mechanism accounts for the persistent anemia affecting approximately 30% of PNH patients on anti-C5 therapy. Pegcetacoplan, a pegylated cyclic peptide C3 inhibitor, binds C3 and C3b directly and prevents all downstream complement effects including both MAC formation and C3b opsonization, making it more complete than anti-C5 therapy for patients with clinically significant extravascular hemolysis; it is administered subcutaneously twice weekly.
Option A: Option A is incorrect because ravulizumab has the same mechanism as eculizumab (C5 blockade) and would not address extravascular hemolysis driven by C3b opsonization, which occurs upstream of C5.
Option B: Option B is incorrect because ravulizumab's extended half-life eliminates trough periods of C5 exposure, but this is not the mechanism of extravascular hemolysis; C3b deposition is not dependent on eculizumab dosing gaps.
Option C: Option C is incorrect because while danicopan is approved as an add-on to anti-C5 therapy for extravascular hemolysis via alternative pathway Factor D inhibition, the mechanism described — C5a-driven macrophage activation — conflates C5a signaling with C3b-opsonization-driven phagocytosis; these are distinct processes.
Option D: Option D is incorrect because anti-C5 therapy does not paradoxically upregulate C3 convertase; the residual C3b deposition is simply the normal upstream complement activity that anti-C5 therapy was never designed to block, not a drug-induced amplification.
11. A 39-year-old woman with refractory myasthenia gravis continues to have high anti-AChR (anti-acetylcholine receptor) antibody titers and severe weakness despite rituximab, high-dose corticosteroids, and plasmapheresis. Her neurologist explains that the persistence of anti-AChR antibodies despite B-cell depletion indicates that a specific long-lived cell population is maintaining antibody production and that a different targeted agent is needed. Which of the following agents targets the key antigen expressed on this cell population, and through what mechanisms does it deplete those cells?
A) Abatacept, which blocks CD80/86 co-stimulation on antigen-presenting cells and prevents the T-follicular helper cell activation required for plasmablast and plasma cell differentiation, thereby cutting off new plasma cell generation.
B) Belimumab, which neutralizes BAFF (B-cell activating factor) and deprives long-lived plasma cells of the survival signals they require in bone marrow niches, causing gradual depletion of the plasma cell pool over months to years.
C) Daratumumab, a fully human anti-CD38 monoclonal antibody; CD38 is highly expressed on long-lived plasma cells, and daratumumab depletes them through antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells and macrophages, complement-dependent cytotoxicity (CDC), ADCP (antibody-dependent cellular phagocytosis), and direct apoptosis induction.
D) Bortezomib, which inhibits the 26S proteasome and induces UPR (unfolded protein response)-mediated apoptosis specifically in antibody-secreting long-lived plasma cells; it is the only plasma cell-directed agent that does not require a specific surface antigen target.
E) Ixazomib, which is an oral proteasome inhibitor that selectively penetrates bone marrow plasma cell niches and induces UPR-driven plasma cell apoptosis, providing superior access to the plasma cell survival compartment compared to intravenous bortezomib.
ANSWER: C
Rationale:
Long-lived plasma cells are the cell population maintaining pathogenic anti-AChR autoantibody production despite rituximab therapy in this patient; they have lost CD20 expression and are therefore invisible to anti-CD20 therapy. Daratumumab is a fully human IgG1 monoclonal antibody directed against CD38 (cluster of differentiation 38), a transmembrane glycoprotein highly expressed on plasma cells (both neoplastic myeloma cells and non-neoplastic long-lived plasma cells) and plasmablasts. Daratumumab depletes CD38-expressing cells through four effector mechanisms: ADCC (antibody-dependent cellular cytotoxicity) mediated by NK cells and macrophages engaging the daratumumab Fc region; CDC (complement-dependent cytotoxicity) via classical pathway activation; ADCP (antibody-dependent cellular phagocytosis) by macrophages; and direct induction of apoptosis through CD38 receptor signaling. In case series of refractory antibody-mediated autoimmune diseases including myasthenia gravis, pemphigus vulgaris, and anti-GBM (glomerular basement membrane) nephritis, daratumumab has shown rapid and deep reductions in pathogenic autoantibody titers.
Option A: Option A is incorrect because abatacept blocks T-cell co-stimulation and would prevent new plasmablast generation but cannot eliminate already-established long-lived plasma cells in bone marrow niches; it does not target a plasma cell surface antigen.
Option B: Option B is incorrect because belimumab targets BAFF and has some effect on plasma cell survival, but its primary clinical effect is on B-cell survival and maturation; it has not demonstrated potent depletion of established long-lived plasma cells comparable to daratumumab.
Option D: Option D is incorrect because while bortezomib is an effective plasma cell-directed therapy via proteasome inhibition, it is not the anti-CD38 antibody being described; the question asks for the agent targeting CD38, which daratumumab specifically addresses.
Option E: Option E is incorrect because ixazomib is an oral proteasome inhibitor used primarily in myeloma; it shares bortezomib's proteasome inhibition mechanism but is not an anti-CD38 monoclonal antibody, and the question is specifically about the CD38-targeting approach.
12. A 72-year-old man with chronic inflammatory demyelinating polyneuropathy (CIDP) receives his monthly IVIG infusion at a rate of 150 mg/kg/hour. Three days later he presents with calf pain and swelling; a duplex ultrasound confirms a deep vein thrombosis (DVT). He has a history of hypertension, type 2 diabetes, and a prior MI. Which of the following best describes the mechanism underlying IVIG-associated thromboembolic events and the patient characteristic that most increases his risk?
A) IVIG transiently suppresses natural anticoagulants (protein C and protein S) through Fc-gamma receptor-mediated hepatocyte signaling, producing a transient procoagulant state; the risk is greatest in patients with pre-existing hepatic synthetic dysfunction.
B) IVIG infusion increases plasma viscosity and promotes platelet aggregation through mechanisms related to high peak IgG concentrations, raising thromboembolic risk; this risk is amplified in older patients with pre-existing cardiovascular risk factors such as hypertension, diabetes, and prior MI, and is reduced by slower infusion rates and adequate hydration.
C) Immune thrombocytopenia triggered by IVIG — through anti-platelet antibodies present in some donor-pooled preparations — causes platelet clumping and microthrombus formation in large veins; the risk correlates with total IgG dose received.
D) IVIG contains vasoactive IgG aggregates that activate the contact activation (kallikrein-kinin) pathway, generating thrombin and triggering deep vein thrombosis; the risk is highest in patients with Factor XII deficiency.
E) High-dose IVIG causes direct endothelial activation through Fc-gamma receptor signaling on endothelial cells, upregulating tissue factor expression and initiating the extrinsic coagulation cascade in large vessels; infusion site matters because peripheral veins are more susceptible.
ANSWER: B
Rationale:
IVIG-associated thromboembolic events — including DVT, pulmonary embolism (PE), myocardial infarction (MI), and stroke — represent one of the most clinically significant serious adverse effects of IVIG. The mechanism involves IVIG-induced increases in plasma viscosity (due to the massive IgG protein load) and promotion of platelet aggregation at high IgG concentrations, creating a prothrombotic state. Risk is substantially higher in patients with pre-existing cardiovascular risk factors (older age, hypertension, diabetes, obesity, prior cardiovascular events, immobility) and in those receiving higher doses or faster infusion rates. Risk-reduction strategies include infusing at lower rates (particularly in high-risk patients), ensuring adequate hydration before and during infusion, and considering prophylactic anticoagulation in very high-risk patients.
Option A: Option A is incorrect because IVIG does not suppress protein C or protein S; the thromboembolic mechanism is viscosity-related and platelet-related, not driven by Fc-gamma receptor signaling on hepatocytes or acquired coagulation factor deficiency.
Option C: Option C is incorrect because IVIG-associated hemolytic anemia occurs through anti-blood-group antibodies in some preparations, but platelet clumping and microthrombus formation in large veins is not the recognized mechanism of IVIG-related DVT; the mechanism is increased viscosity and platelet aggregation.
Option D: Option D is incorrect because the contact activation pathway and Factor XII deficiency are not the mechanism of IVIG thromboembolism; this is a fabricated pharmacological construct not consistent with established IVIG adverse effect mechanisms.
Option E: Option E is incorrect because direct endothelial Fc-gamma receptor activation triggering tissue factor upregulation is not the established mechanism of IVIG thromboembolism; while endothelial effects of IVIG exist, the dominant mechanism in clinical thromboembolic events is viscosity and platelet-driven.
13. A 41-year-old woman with PNH is currently on eculizumab but continues to have significant extravascular hemolysis with a hemoglobin of 8.8 g/dL. Her hematologist considers switching to iptacopan, explaining that unlike anti-C5 therapy, this newer oral agent targets a different component of the complement cascade, specifically within the alternative pathway amplification loop. Which of the following best identifies iptacopan's molecular target and explains its clinical advantage in this patient?
A) Iptacopan inhibits Factor D, the serine protease that cleaves Factor B within the assembled alternative pathway C3 convertase complex; by blocking Factor D, it prevents alternative pathway amplification and is approved as add-on therapy to eculizumab in PNH.
B) Iptacopan inhibits C3, preventing all three complement pathways from generating C3b, thereby blocking both intravascular and extravascular hemolysis; it represents the most upstream complement inhibitor currently approved for PNH.
C) Iptacopan inhibits the C5aR1 (C5a receptor 1) on macrophages, preventing C5a-mediated macrophage activation and reticuloendothelial phagocytosis of C3b-opsonized PNH erythrocytes in the liver and spleen.
D) Iptacopan is an oral small-molecule inhibitor of Factor B — the serine protease that associates with C3b to form the alternative pathway C3 convertase (C3bBb) — selectively blocking alternative pathway amplification while leaving the classical and lectin pathways intact; it is approved as monotherapy for PNH and demonstrated superiority over anti-C5 therapy in reducing extravascular hemolysis and improving hemoglobin levels.
E) Iptacopan is an oral inhibitor of properdin (Factor P), the positive regulatory protein that stabilizes the alternative pathway C3 convertase; by destabilizing the convertase complex, it reduces C3b generation on PNH erythrocyte surfaces without affecting the classical or lectin pathways.
ANSWER: D
Rationale:
Iptacopan is an oral small-molecule inhibitor of Factor B (FB), the serine protease that associates with C3b on target surfaces to form the alternative pathway C3 convertase (C3bBb). Factor B is the catalytic subunit of this convertase, and its inhibition prevents alternative pathway amplification — the powerful self-amplification loop that drives the majority of complement activation in PNH once the initial activating event occurs. By blocking alternative pathway amplification, iptacopan reduces C3b deposition on PNH erythrocytes, thereby addressing both the intravascular hemolysis (downstream MAC formation) and extravascular hemolysis (C3b opsonization driving reticuloendothelial phagocytosis). Crucially, the classical and lectin pathways remain intact because Factor B is specific to the alternative pathway. Clinical trial data demonstrated superiority over anti-C5 therapy in reducing extravascular hemolysis and significantly improving hemoglobin levels, and iptacopan is approved as monotherapy for PNH in adults.
Option A: Option A is incorrect because the Factor D inhibitor described is danicopan, not iptacopan; danicopan is approved as add-on therapy to anti-C5, whereas iptacopan is approved as monotherapy.
Option B: Option B is incorrect because C3 inhibition describes the mechanism of pegcetacoplan; iptacopan acts specifically on Factor B within the alternative pathway, not on C3 itself.
Option C: Option C is incorrect because C5aR1 antagonism is the mechanism of avacopan, which is approved for ANCA vasculitis, not PNH; this mechanism would not prevent extravascular hemolysis driven by C3b opsonization.
Option E: Option E is incorrect because properdin (Factor P) inhibition is not the mechanism of iptacopan; properdin is a positive regulator that stabilizes the alternative pathway C3 convertase, but clinically approved inhibitors target Factor B or Factor D, not properdin.
14. A rheumatologist is selecting a biologic agent for a 46-year-old woman with moderate-to-severe RA (rheumatoid arthritis) who has failed methotrexate. Her serologic workup shows strongly positive anti-CCP (anti-cyclic citrullinated peptide) antibodies and rheumatoid factor. The rheumatologist notes that this serologic profile makes abatacept a particularly advantageous choice compared to TNF (tumor necrosis factor) inhibitors. Which of the following best explains this reasoning?
A) Seropositive RA with high anti-CCP and rheumatoid factor reflects T-cell-driven pathology with prominent T-follicular helper cell-mediated germinal center activation; abatacept's T-cell co-stimulation blockade is mechanistically well-matched to this disease subtype, and clinical data support superior or comparable efficacy of abatacept vs. TNF inhibitors specifically in seropositive patients.
B) Anti-CCP antibodies activate the classical complement pathway through Fc-mediated C1q binding, and abatacept's ability to block antigen-presenting cell activation prevents further complement-fixing autoantibody production; TNF inhibitors have no effect on complement-driven synovitis.
C) High-titer rheumatoid factor is associated with elevated TNF receptor shedding from synovial macrophages, which neutralizes circulating TNF inhibitors and reduces their efficacy; abatacept, acting through a TNF-independent pathway, maintains effectiveness in high-rheumatoid-factor patients where TNF inhibitors fail pharmacokinetically.
D) Seropositivity in RA indicates pre-existing B-cell hyperactivation driven by excess BAFF (B-cell activating factor) signaling, and abatacept reduces synovial BAFF levels by blocking the T-follicular helper cell activation required for BAFF induction; TNF inhibitors do not address the BAFF-driven component of B-cell hyperactivation.
E) Anti-CCP antibodies are citrullinated peptide-specific IgM antibodies that are directly neutralized by the anti-idiotypic IgG repertoire in the CTLA-4-Ig fusion protein component of abatacept, reducing anti-CCP titers and synovial inflammation more effectively than TNF inhibitors.
ANSWER: A
Rationale:
Seropositive RA — defined by the presence of anti-CCP (ACPA, anti-citrullinated protein antibody) and/or rheumatoid factor (RF) — is characterized by more prominent T-cell-driven immunopathology, with active T-follicular helper cell-driven germinal center reactions, substantial antigen-specific CD4+ T-cell synovial infiltration, and greater autoantibody production. Abatacept, as a CTLA-4-Ig T-cell co-stimulation blocker, is mechanistically well-suited to interrupt this T-cell-dependent pathway. Multiple clinical studies, including the AMPLE trial comparing abatacept to adalimumab, have demonstrated that seropositivity (particularly anti-CCP positivity) is a predictor of better relative response to abatacept versus TNF inhibitors; some analyses suggest abatacept may be preferred as first biologic specifically in high-titer seropositive patients.
Option B: Option B is incorrect because anti-CCP antibodies do activate complement, but the rationale for preferring abatacept in seropositive RA is based on T-cell pathway dominance, not the complement-activating capacity of anti-CCP; TNF inhibitors are highly effective in reducing synovitis regardless of complement involvement.
Option C: Option C is incorrect because elevated rheumatoid factor does not cause TNF receptor shedding that neutralizes TNF inhibitors; this describes a pharmacokinetically implausible mechanism; the RF titer does not predict TNF inhibitor clearance.
Option D: Option D is incorrect because while abatacept does indirectly reduce B-cell activation by depriving B cells of T-cell help, the mechanism by which it does so is not through BAFF level reduction; BAFF targeting is the mechanism of belimumab, not abatacept.
Option E: Option E is incorrect because abatacept does not contain anti-idiotypic antibodies directed against anti-CCP; it is a CTLA-4-Ig fusion protein that binds CD80/CD86 on APCs and has no direct anti-CCP neutralizing activity.
15. A 52-year-old woman received a living-donor kidney transplant five years ago and has been maintained on tacrolimus-based immunosuppression. Her eGFR (estimated glomerular filtration rate) has declined from 58 mL/min/1.73m² at one year to 41 mL/min/1.73m² at five years, with renal biopsy showing chronic calcineurin inhibitor nephrotoxicity. Her transplant team discusses converting to belatacept. Which of the following best describes the mechanism by which belatacept avoids the renal toxicity seen with calcineurin inhibitors?
A) Belatacept is cleared renally and does not accumulate in renal tubular cells, whereas tacrolimus concentrates in tubular epithelial cells through organic cation transporters and causes direct mitochondrial toxicity and tubular necrosis.
B) Belatacept blocks T-cell activation but preserves regulatory T-cell function, which suppresses TGF-beta (transforming growth factor-beta) production in the allograft; tacrolimus paradoxically upregulates TGF-beta, driving interstitial fibrosis and tubular atrophy.
C) Belatacept has no CYP3A4 (cytochrome P450 3A4) drug interactions unlike tacrolimus, eliminating the drug level variability that drives tacrolimus nephrotoxicity through unpredictable peak concentration spikes.
D) Belatacept blocks calcineurin phosphatase activity upstream of the NFAT (nuclear factor of activated T cells) pathway, providing equivalent immunosuppression to tacrolimus without the afferent arteriolar vasoconstriction that causes tacrolimus-induced nephrotoxicity.
E) Belatacept, unlike calcineurin inhibitors, does not cause afferent arteriolar vasoconstriction, tubular toxicity, or pro-fibrotic TGF-beta upregulation; because it acts at the T-cell co-stimulation checkpoint rather than intraneuronally, it preserves renal hemodynamics and microvasculature, and patients on belatacept-based regimens maintain better long-term eGFR and lower rates of chronic allograft nephropathy compared to calcineurin inhibitor-based maintenance.
ANSWER: E
Rationale:
Calcineurin inhibitors (tacrolimus and cyclosporine) cause renal toxicity through multiple mechanisms: afferent arteriolar vasoconstriction leading to reduced renal perfusion and glomerular filtration; direct tubular epithelial toxicity; upregulation of TGF-beta (transforming growth factor-beta) in the renal interstitium, driving fibrosis and tubular atrophy; and thrombotic microangiopathy in some cases. These effects are dose-dependent and cumulative, causing progressive chronic allograft nephropathy and decline in eGFR over years of treatment. Belatacept's mechanism — blockade of CD80/CD86-CD28 T-cell co-stimulation — has no direct pharmacological effect on renal vasculature, tubular cells, or TGF-beta production; it acts exclusively at the level of T-cell activation in lymphoid tissue. Long-term registry and clinical trial data demonstrate that patients maintained on belatacept have significantly better eGFR preservation and lower rates of chronic allograft nephropathy compared to those on calcineurin inhibitor-based regimens.
Option A: Option A is incorrect because the mechanism of calcineurin inhibitor nephrotoxicity is primarily vasoconstriction and TGF-beta-mediated fibrosis, not organic cation transporter-mediated mitochondrial toxicity; this option inaccurately describes the mechanism.
Option B: Option B is incorrect because while TGF-beta upregulation is a component of calcineurin inhibitor nephrotoxicity, the premise that belatacept preserves regulatory T-cell function and thereby suppresses TGF-beta is mechanistically inaccurate; the nephroprotective benefit of belatacept is the absence of direct renal pharmacological toxicity, not TGF-beta suppression.
Option C: Option C is incorrect because while tacrolimus does have extensive CYP3A4 interactions that require careful TDM, variable drug levels are not the primary mechanism of calcineurin inhibitor nephrotoxicity; the toxicity occurs even in well-managed patients with appropriate trough levels.
Option D: Option D is incorrect because belatacept does not inhibit calcineurin phosphatase activity; it acts at the T-cell surface co-stimulation checkpoint entirely upstream of calcineurin and NFAT; this option describes a mechanism that conflates belatacept with calcineurin inhibitor pharmacology.
16. A rheumatologist reviews a cohort of patients with pemphigus vulgaris — an antibody-mediated blistering skin disease driven by anti-desmoglein IgG autoantibodies — who achieved initial improvement after rituximab but then relapsed with persistently elevated anti-desmoglein titers six months after B-cell depletion was confirmed by flow cytometry. She explains to her fellow that the relapse mechanism reflects a fundamental limitation of anti-CD20 therapy in antibody-mediated autoimmune disease. Which of the following best explains this limitation?
A) Rituximab selectively depletes naive and transitional B cells but preserves memory B cells, which rapidly redifferentiate into antibody-secreting cells after the drug is discontinued, regenerating the pathogenic autoantibody response within weeks of treatment.
B) Rituximab targets CD20 on B cells, but peripheral tolerance to desmoglein antigens is maintained by follicular regulatory T cells (Tfr); rituximab inadvertently depletes Tfr cells that co-express low levels of CD20, removing the germinal center brake and accelerating autoantibody re-emergence.
C) Rituximab depletes CD20-expressing B cells but cannot eliminate long-lived plasma cells, which have terminally differentiated, exited the cell cycle, and lost CD20 expression; these long-lived plasma cells persist in protected bone marrow niches and continue secreting pathogenic anti-desmoglein autoantibodies for months to years regardless of circulating B-cell levels.
D) Rituximab is effectively neutralized by anti-drug antibodies (ADAs) that develop during the first course and prevent adequate B-cell depletion during re-treatment; the relapse of anti-desmoglein titers reflects insufficient drug exposure rather than pharmacological evasion by a specific cell population.
E) Rituximab does not cross into the skin dermis where the pathogenic anti-desmoglein antibodies are concentrated, leaving a tissue reservoir of intact B cells and plasma cells protected from systemic CD20 depletion; local anti-CD20 injection into lesional skin would be required to address this compartmental limitation.
ANSWER: C
Rationale:
Long-lived plasma cells are terminally differentiated antibody-secreting cells that have completed somatic hypermutation and affinity maturation in germinal centers, then differentiated into non-dividing secretory cells that migrate to and persist in specialized bone marrow survival niches. The critical feature that makes them invisible to rituximab is the loss of CD20 expression upon terminal plasma cell differentiation: CD20 is expressed on B cells from the pre-B cell stage through memory B cells but is absent on plasmablasts and mature plasma cells. This means that even complete peripheral B-cell depletion by rituximab leaves the established plasma cell pool intact and secreting autoantibodies from the bone marrow. In pemphigus vulgaris, myasthenia gravis, membranous nephropathy, and other antibody-mediated autoimmune diseases, this plasma cell reservoir maintains pathogenic autoantibody titers for months to years after rituximab-mediated B-cell depletion, explaining the characteristic pattern of initial improvement followed by relapse as new B cells eventually reconstitute the plasmablast pool.
Option A: Option A is incorrect because rituximab depletes both naive and memory B cells (both express CD20); memory B cells are depleted by rituximab; the resistance to rituximab is not due to memory B-cell sparing but to long-lived plasma cell CD20 negativity.
Option B: Option B is incorrect because follicular regulatory T cells (Tfr) do not express CD20; they are T cells and are not depleted by rituximab; this option describes a pharmacologically implausible mechanism.
Option D: Option D is incorrect because anti-drug antibody formation to rituximab does occur but is not the primary explanation for the pattern of disease relapse described; the question describes confirmed B-cell depletion by flow cytometry, ruling out inadequate drug exposure as the cause.
Option E: Option E is incorrect because rituximab works through circulating depletion of systemic B-cell populations; anti-desmoglein antibodies are produced by bone marrow plasma cells and secreted into circulation, not by dermal B cells; there is no tissue sanctuary effect in the skin that rituximab cannot access.
17. A 32-year-old woman with SLE (systemic lupus erythematosus) has persistently active skin and musculoskeletal disease despite hydroxychloroquine and low-dose prednisone. Her rheumatologist is considering anifrolumab — a monoclonal antibody targeting the type I interferon receptor (IFNAR1) — and orders a specific biomarker test to assess the likelihood of response. Which of the following biomarkers best predicts response to anifrolumab and explains why a negative result might lead to choosing a different biologic?
A) Anti-dsDNA antibody titers, because anifrolumab reduces anti-dsDNA production by blocking interferon-driven B-cell class-switching; patients with low anti-dsDNA titers lack the immunological target for interferon pathway blockade and are better served by belimumab.
B) Serum complement C3 and C4 levels, because low complement consumption (normal C3/C4) indicates predominantly T-cell-driven rather than immune complex-driven lupus; anifrolumab is specifically effective only when complement activation is ongoing and cannot modulate complement-independent lupus disease activity.
C) The blood eosinophil count, because type I interferons suppress eosinophil survival and anifrolumab-mediated IFNAR1 blockade restores normal eosinophil levels; a high baseline eosinophil count is the strongest predictor of clinical response to anifrolumab in SLE.
D) The interferon gene signature (ISG) score — a measure of type I interferon pathway activation detected by gene expression profiling of peripheral blood cells — is positive in 60 to 80% of SLE patients; a high ISG score identifies patients more likely to respond to anifrolumab, while a low ISG score may indicate T-cell-predominant or BAFF-driven disease better served by conventional immunosuppression or belimumab.
E) Serum BAFF (B-cell activating factor) levels, because elevated BAFF is the major driver of type I interferon production in SLE; anifrolumab directly blocks BAFF signaling downstream of IFNAR1 activation, and a low BAFF level predicts inadequate therapeutic target engagement.
ANSWER: D
Rationale:
Type I interferons (interferon-alpha and interferon-beta) play a central pathogenic role in SLE, but the degree of interferon pathway activation varies substantially among patients. The interferon gene signature (ISG) score is derived from peripheral blood gene expression profiling and reflects the transcriptional activation of interferon-stimulated genes (ISGs), indicating ongoing type I interferon pathway activity. Approximately 60 to 80% of SLE patients have a positive (high) ISG score, and this subset demonstrates significantly greater clinical response to anifrolumab — which blocks the type I interferon receptor IFNAR1 — compared to patients with a negative (low) ISG score, who may have disease driven predominantly by other pathways (T-cell-mediated, complement-mediated, or BAFF-driven B-cell hyperactivation). This represents one of the clearest examples of precision immunopharmacology: a specific biomarker guiding biologic selection based on the dominant immunopathological mechanism in an individual patient.
Option A: Option A is incorrect because anti-dsDNA antibody titers reflect disease activity and lupus nephritis risk, but they are not the established predictive biomarker for anifrolumab response; they do not directly indicate the degree of type I interferon pathway activation driving disease in a given patient.
Option B: Option B is incorrect because complement C3/C4 levels reflect complement consumption (immune complex-driven activation) and are used to monitor SLE disease activity and lupus nephritis, but they are not the biomarker that predicts response to anifrolumab; complement levels are not a surrogate for interferon pathway activation.
Option C: Option C is incorrect because the blood eosinophil count is the established biomarker for anti-IL-5 biologic selection in severe asthma (mepolizumab, benralizumab), not a predictor of anifrolumab response in SLE; type I interferons do not regulate eosinophil survival in the manner described.
Option E: Option E is incorrect because serum BAFF levels guide belimumab therapy selection, not anifrolumab; BAFF is not a downstream product of IFNAR1 activation, and the option incorrectly attributes BAFF modulation to anifrolumab's mechanism.
18. A 61-year-old man with RA is maintained on tocilizumab and develops a fever of 38.9°C with productive cough and hypoxia. His CRP (C-reactive protein) is 4 mg/L (normal). His rheumatologist explains to the covering resident that this CRP result cannot be relied upon to exclude serious infection and orders procalcitonin instead. Which of the following best explains why CRP loses its utility as an infection biomarker in patients on tocilizumab?
A) Tocilizumab induces production of CRP-binding proteins that sequester circulating CRP in immune complexes, reducing measured serum CRP levels without affecting actual CRP synthesis; procalcitonin is unaffected because it is not bound by these complexes.
B) Tocilizumab blocks the IL-6 receptor (IL-6R), and IL-6 (interleukin-6) is the primary inducer of hepatic CRP synthesis through JAK-STAT3 (Janus kinase-signal transducer and activator of transcription 3) signaling; when IL-6R is blocked, CRP synthesis is suppressed even in the presence of active infection or inflammation, making CRP a falsely reassuring biomarker; procalcitonin production is driven by IL-6-independent pathways (primarily bacterial endotoxin and TNF) and remains elevated in bacterial infection despite IL-6R blockade.
C) Tocilizumab upregulates hepatic CRP clearance by inducing complement receptor 1 (CR1) expression on Kupffer cells, accelerating CRP catabolism and reducing its serum half-life from 19 hours to less than 6 hours; this does not affect procalcitonin because it is cleared renally rather than by hepatic phagocytes.
D) CRP is unreliable in tocilizumab-treated patients because the drug directly binds CRP through its Fc region in serum, forming drug-CRP complexes that are rapidly cleared by FcRn recycling; procalcitonin lacks Fc-binding properties and is unaffected by tocilizumab.
E) Tocilizumab depletes circulating monocytes — the primary source of CRP — by blocking IL-6-driven monocyte survival signals, reducing baseline CRP production capacity; procalcitonin is superior because it is produced by parenchymal cells rather than monocytes and is not affected by tocilizumab-related monocytopenia.
ANSWER: B
Rationale:
CRP (C-reactive protein) is synthesized by hepatocytes in response to pro-inflammatory cytokines, most importantly IL-6 (interleukin-6), which signals through the IL-6 receptor to activate the JAK-STAT3 transcription pathway and induce acute-phase protein production including CRP, fibrinogen, serum amyloid A, and ferritin. Tocilizumab and sarilumab are anti-IL-6R monoclonal antibodies that block IL-6 signaling at the receptor level; this results in pharmacological suppression of CRP synthesis independent of actual inflammatory or infectious stimulus. Patients on IL-6R inhibitors therefore have constitutively suppressed CRP even during serious bacterial infections — making CRP a dangerously unreliable infection biomarker in this setting. Procalcitonin (PCT) production is driven primarily by bacterial endotoxin (lipopolysaccharide), IL-1beta, and TNF through IL-6-independent pathways; it rises normally during bacterial infection in patients on tocilizumab and is the preferred infection biomarker in this population. This distinction is critically important clinically: a normal CRP in a patient on tocilizumab with fever may falsely reassure the clinician and delay antibiotic therapy for a life-threatening infection.
Option A: Option A is incorrect because tocilizumab does not produce CRP-binding proteins that sequester CRP in immune complexes; the drug blocks the IL-6 receptor at the cellular level, suppressing CRP transcription and synthesis rather than increasing its clearance.
Option C: Option C is incorrect because tocilizumab does not upregulate Kupffer cell complement receptor 1 or accelerate hepatic CRP catabolism; the suppression is at the level of synthesis (gene transcription), not clearance.
Option D: Option D is incorrect because tocilizumab does not bind CRP directly; it is an anti-IL-6 receptor antibody, not a CRP-binding protein; drug-CRP complexes are a fabricated mechanism.
Option E: Option E is incorrect because CRP is produced by hepatocytes, not monocytes; and tocilizumab does not cause clinically significant monocytopenia; the mechanism is hepatic CRP synthesis suppression through IL-6R blockade.
19. A 67-year-old man with CLL (chronic lymphocytic leukemia) is started on ibrutinib and develops atrial fibrillation (AF) six weeks later. His cardiologist asks why BTK (Bruton tyrosine kinase) inhibitors cause AF and whether switching to acalabrutinib would reduce this risk. Which of the following best explains the mechanism of ibrutinib-associated AF and how second-generation BTK inhibitors address it?
A) Ibrutinib is a first-generation covalent BTK inhibitor that, in addition to BTK, inhibits multiple off-target kinases including ITK (interleukin-2-inducible T-cell kinase) and EGFR (epidermal growth factor receptor), which are involved in cardiac conduction pathways; this off-target inhibition disrupts atrial electrophysiology and promotes AF in approximately 10 to 16% of patients. Acalabrutinib and zanubrutinib are second-generation covalent BTK inhibitors with greater BTK selectivity and substantially lower off-target kinase inhibition, conferring a significantly lower rate of AF.
B) Ibrutinib causes AF by inhibiting BTK in cardiac sinoatrial nodal cells, where BTK regulates potassium channel phosphorylation; because cardiac BTK expression is identical to B-cell BTK expression, second-generation agents with the same BTK selectivity profile as ibrutinib have equivalent AF risk.
C) Ibrutinib-associated AF is caused by direct cardiotoxicity from ibrutinib's boronic acid functional group, which binds and inhibits cardiac proteasome activity in myocytes; second-generation BTK inhibitors lack this boronic acid group and therefore avoid this cardiac toxicity.
D) Ibrutinib depletes circulating BTK-expressing platelets, impairing thrombus formation and allowing micro-thromboemboli to reach the cardiac conduction system and trigger AF; acalabrutinib has lower anti-platelet activity because it preferentially inhibits B-cell BTK over platelet BTK.
E) Ibrutinib causes AF through Fc-gamma receptor-independent complement activation on atrial endothelial cells, triggering localized MAC deposition in atrial tissue; second-generation agents have modified Fc regions that reduce complement-dependent cardiotoxicity.
ANSWER: A
Rationale:
Ibrutinib is a first-generation covalent (irreversible) BTK inhibitor that forms a covalent bond with cysteine-481 in the BTK active site. In addition to BTK, ibrutinib inhibits a range of related kinases sharing the Cys-481 binding site, most importantly ITK (IL-2-inducible T-cell kinase), EGFR (epidermal growth factor receptor), TEC, and RLK (also called TXK). ITK and EGFR are expressed in cardiac tissue and are involved in atrial electrophysiology and conduction; their off-target inhibition by ibrutinib is believed to disrupt atrial electrical signaling and promote AF, which occurs in approximately 10 to 16% of ibrutinib-treated patients — a rate substantially higher than in the general population with CLL of similar age. Second-generation BTK inhibitors, acalabrutinib and zanubrutinib, were engineered with greater BTK selectivity through structural modifications that reduce binding to these off-target kinases; both demonstrate substantially lower rates of AF in clinical trials compared to ibrutinib.
Option B: Option B is incorrect because BTK is not expressed in sinoatrial nodal cells as a major electrophysiological regulator; the cardiac mechanism is through off-target kinase inhibition, not through direct BTK inhibition in cardiac pacemaker cells; and second-generation agents do have lower AF rates precisely because of reduced off-target inhibition.
Option C: Option C is incorrect because ibrutinib does not contain a boronic acid functional group — that is the chemical feature of bortezomib (a proteasome inhibitor, not a BTK inhibitor); ibrutinib is an acrylamide-containing inhibitor.
Option D: Option D is incorrect because ibrutinib does inhibit platelet BTK and impairs platelet aggregation — which increases bleeding risk — but platelet depletion causing AF through micro-thromboemboli to the conduction system is not the established mechanism; the mechanism is off-target kinase inhibition affecting atrial electrophysiology.
Option E: Option E is incorrect because ibrutinib-associated AF does not involve Fc-gamma receptor-independent complement activation or MAC deposition in atrial tissue; this is a pharmacologically fabricated mechanism unrelated to BTK inhibitor cardiotoxicity.
20. A 44-year-old woman with newly diagnosed RA is about to start methotrexate and etanercept. During pre-treatment review, her rheumatologist notes she is not up to date on her MMR (measles-mumps-rubella) vaccine and has not received the varicella vaccine. The physician explains that one type of vaccine cannot be administered once immunosuppressive therapy begins, but other vaccines can be given throughout treatment. Which of the following best explains this distinction and the underlying safety rationale?
A) Protein subunit vaccines such as the recombinant zoster vaccine (Shingrix) cannot be administered during immunosuppressive therapy because the adjuvant (AS01B) triggers robust innate immune activation that may precipitate disease flare; all live attenuated vaccines are safe to administer at any time because they generate durable immunity before immunosuppression reduces vaccine-strain clearance.
B) Inactivated vaccines such as the inactivated influenza vaccine cannot be given during immunosuppressive therapy because the immune response is insufficient to generate protective antibody titers; live attenuated vaccines should be given instead, as the replicating vaccine strain generates more robust immunogenicity even in immunosuppressed individuals.
C) Conjugate polysaccharide vaccines such as the pneumococcal conjugate vaccine (PCV) require functional T-cell help and cannot induce protective immunity in patients on T-cell-targeting biologics such as abatacept; live attenuated vaccines are safe in patients on abatacept because it spares innate immune pathways.
D) All vaccines — live attenuated and inactivated — are contraindicated during TNF inhibitor therapy because TNF is required for granuloma formation that contains both vaccine-strain organisms and natural pathogens; etanercept specifically blocks all TNF-mediated granuloma maintenance.
E) Live attenuated vaccines (including MMR, varicella, yellow fever, and live-attenuated influenza vaccine) are contraindicated once any significant immunosuppressive therapy is started because vaccine-strain organisms may cause disseminated infection in the absence of normal immune surveillance; inactivated, subunit, and conjugate vaccines can be administered throughout immunosuppressive therapy, though immunogenicity may be reduced, and should ideally be completed before treatment begins.
ANSWER: E
Rationale:
Live attenuated vaccines contain viable, replication-competent vaccine-strain organisms — viruses or bacteria that have been weakened but retain the ability to infect and replicate in the vaccinated host. In immunocompetent individuals, the attenuated organism is controlled by normal immune surveillance while generating protective immunity. In immunosuppressed patients, however, the attenuated vaccine organism may replicate unchecked and cause disseminated infection clinically indistinguishable from natural infection; for example, live varicella vaccine can cause disseminated varicella zoster disease, MMR vaccine can cause measles or rubella-like illness, and live-attenuated influenza vaccine (LAIV) can cause influenza in immunocompromised hosts. This safety concern applies across all classes of immunosuppressive therapy including biologics (TNF inhibitors, rituximab, IL-6R inhibitors), JAK inhibitors, and traditional immunosuppressants (methotrexate, azathioprine). Inactivated, subunit, toxoid, and conjugate vaccines contain no live organisms and cannot cause infection; they can be administered throughout immunosuppressive therapy (though response may be attenuated), and are recommended including annual inactivated influenza, pneumococcal, and COVID-19 vaccines.
Option A: Option A is incorrect because it reverses the correct safety guidance: inactivated vaccines including Shingrix can be safely administered during immunosuppressive therapy; live attenuated vaccines are the ones that are contraindicated, not the subunit vaccines.
Option B: Option B is incorrect because it also reverses the correct guidance: inactivated vaccines are safe during immunosuppression and should be used; live vaccines are contraindicated, not preferred.
Option C: Option C is incorrect because conjugate vaccines are safe during T-cell-targeting biologic therapy (though immunogenicity may be reduced); and live vaccines are not safe in patients on abatacept despite its being a co-stimulation blocker rather than a direct cytokine inhibitor.
Option D: Option D is incorrect because not all vaccines are contraindicated on TNF inhibitor therapy; only live attenuated vaccines are contraindicated; inactivated vaccines are safe and recommended.
21. A 33-year-old man with PNH has been on eculizumab for three years with excellent control of intravascular hemolysis. However, he has persistent anemia with hemoglobin 9.4 g/dL and his hematologist confirms ongoing extravascular hemolysis by elevated reticulocyte count and elevated indirect bilirubin. His physician considers adding a second complement inhibitor targeting a different component of the alternative pathway rather than switching from eculizumab entirely. Which of the following agents is approved specifically as add-on therapy to anti-C5 treatment for this indication, and what is its target?
A) Iptacopan, an oral Factor B inhibitor, is approved as add-on therapy to eculizumab or ravulizumab for PNH patients with persistent extravascular hemolysis; it selectively blocks alternative pathway C3 convertase assembly while leaving anti-C5 MAC inhibition intact.
B) Pegcetacoplan, a C3 inhibitor, is approved as add-on therapy to anti-C5 treatment for residual extravascular hemolysis; by blocking C3 upstream of anti-C5's target, pegcetacoplan provides additive protection and the combination is the preferred treatment for patients with significant extravascular hemolysis on eculizumab.
C) Avacopan, an oral C5aR1 (C5a receptor 1) antagonist, is approved as add-on therapy to eculizumab for PNH patients with extravascular hemolysis; by blocking C5a-mediated macrophage activation in the reticuloendothelial system, it reduces phagocytosis of C3b-opsonized PNH erythrocytes.
D) Danicopan, an oral Factor D inhibitor that blocks the serine protease responsible for cleaving Factor B within the alternative pathway C3 convertase complex, is approved specifically as add-on therapy to eculizumab or ravulizumab in PNH patients with clinically significant extravascular hemolysis that persists despite anti-C5 therapy.
E) Ravulizumab, a long-acting anti-C5 monoclonal antibody with a half-life of 49 to 52 days, is approved as add-on therapy to eculizumab for PNH patients with extravascular hemolysis uncontrolled on the shorter-acting agent; the combination provides more complete C5 blockade and eliminates trough-period C3b deposition.
ANSWER: D
Rationale:
Danicopan is an oral small-molecule inhibitor of Factor D (FD), the serine protease that cleaves Factor B within the assembled alternative pathway C3 convertase complex; by preventing Factor B cleavage, danicopan blocks assembly and activity of the C3 convertase C3bBb, reducing C3b generation on PNH erythrocyte surfaces and thereby addressing the extravascular hemolysis that persists on anti-C5 therapy. Danicopan was specifically approved as add-on therapy to eculizumab or ravulizumab for PNH patients with clinically significant extravascular hemolysis that is not adequately controlled by anti-C5 therapy alone; it reduces C3b opsonization and reticuloendothelial phagocytosis while leaving the MAC-blocking benefit of the anti-C5 agent intact. As a selective alternative pathway inhibitor, danicopan carries meningococcal vaccination requirements.
Option A: Option A is incorrect because iptacopan is approved as monotherapy for PNH (not as add-on therapy to anti-C5); it targets Factor B (not Factor D); and the approved indication is monotherapy replacement of anti-C5, not combination use.
Option B: Option B is incorrect because pegcetacoplan is approved as monotherapy for PNH (replacing anti-C5 therapy), not as add-on combination therapy with eculizumab; combining a C3 inhibitor with anti-C5 therapy is not the approved or recommended approach.
Option C: Option C is incorrect because avacopan is approved for ANCA-associated vasculitis, not for PNH; C5a-mediated macrophage activation is not the primary mechanism of extravascular hemolysis in PNH (C3b opsonization is); and avacopan is not approved as add-on PNH therapy.
Option E: Option E is incorrect because ravulizumab and eculizumab are both anti-C5 agents with the same mechanism and are not co-administered; the approved strategy is to switch from eculizumab to ravulizumab (not add ravulizumab to eculizumab), and this combination would not address extravascular hemolysis since both agents block at C5, leaving C3b deposition intact.
22. A hematology fellow is counseled by her attending on the principles of precision medicine applied to complement inhibitor selection in PNH. The attending explains that in PNH, specific laboratory parameters and clinical features — rather than one-size-fits-all treatment — should guide which complement inhibitor is most appropriate for a given patient. Which of the following best reflects the current biomarker-guided approach to complement inhibitor selection in PNH?
A) Serum C3 and C4 levels determine complement inhibitor selection in PNH: patients with low C3 from alternative pathway over-activity require anti-C5 therapy to reduce C5a-mediated neutrophil activation, while patients with low C4 from classical pathway activation should receive pegcetacoplan to block the initial trigger of complement in PNH erythrocytes.
B) Anti-CD55 and anti-CD59 autoantibody titers determine complement inhibitor selection: patients with primarily anti-CD59 antibodies driving MAC-mediated intravascular hemolysis should receive eculizumab, while patients with anti-CD55 antibodies driving C3b opsonization should receive pegcetacoplan.
C) PNH clone size (the proportion of GPI-deficient blood cells detected by flow cytometry) and the pattern of hemolysis — intravascular versus extravascular — guide complement inhibitor selection: patients with predominantly intravascular hemolysis are well served by anti-C5 therapy (eculizumab or ravulizumab), while patients with significant residual extravascular hemolysis or those preferring oral therapy may be better suited to pegcetacoplan (C3 inhibitor) or iptacopan (Factor B inhibitor as monotherapy).
D) PIGA (phosphatidylinositol glycan biosynthesis class A) mutation variant type and location determine complement inhibitor selection: missense mutations respond preferentially to anti-C5 therapy, while frameshift mutations cause more severe GPI deficiency requiring proximal complement inhibition with pegcetacoplan or iptacopan.
E) Renal function (eGFR) is the primary determinant of complement inhibitor selection in PNH: patients with eGFR above 60 mL/min/1.73m² receive anti-C5 therapy, while those with renal impairment require dose-adjusted oral Factor B inhibitors to avoid the nephrotoxic metabolites generated by intravenous anti-C5 monoclonal antibodies.
ANSWER: C
Rationale:
Precision immunopharmacology in PNH uses two primary biomarkers to guide complement inhibitor selection. Clone size — the proportion of GPI (glycosylphosphatidylinositol)-deficient granulocytes, monocytes, and erythrocytes detected by high-sensitivity flow cytometry — reflects the burden of complement-susceptible cells; larger clones generally indicate higher disease activity and greater need for complement inhibition. Equally important is the characterization of hemolysis pattern: patients with predominantly intravascular hemolysis (elevated LDH, hemoglobinuria, thrombotic events) are the classical responders to anti-C5 therapy (eculizumab or ravulizumab), which is highly effective at preventing MAC-mediated lysis. However, approximately 30% of PNH patients on anti-C5 therapy have clinically significant residual extravascular hemolysis (persistent anemia with elevated reticulocyte count and bilirubin without hemoglobinuria) due to ongoing C3b opsonization that anti-C5 therapy cannot address; these patients may be better served by proximal C3 inhibition with pegcetacoplan or by alternative pathway blockade with iptacopan as oral monotherapy. Patient preference for oral versus intravenous therapy, venous access, and the severity of thrombocytopenia (if present) also factor into the decision.
Option A: Option A is incorrect because serum C3 and C4 levels as described do not drive complement inhibitor selection in PNH; PNH is caused by somatic PIGA mutations causing GPI-anchor deficiency, not by autoantibodies against complement proteins; the C3/C4 framework described is inaccurate.
Option B: Option B is incorrect because PNH is not caused by anti-CD55 or anti-CD59 autoantibodies; it is caused by loss of GPI-anchored CD55 and CD59 from erythrocyte surfaces due to somatic PIGA gene mutation; autoantibody-based selection criteria are pharmacologically fabricated.
Option D: Option D is incorrect because PIGA mutation type (missense vs. frameshift) does not determine complement inhibitor selection; the clinical decision is based on hemolysis pattern and laboratory parameters, not on the specific PIGA mutation variant.
Option E: Option E is incorrect because eGFR does not determine complement inhibitor selection in PNH; anti-C5 monoclonal antibodies are not nephrotoxic, and oral Factor B inhibitors are not specifically indicated in renal impairment as a safety-driven selection criterion.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.